Aspen Pharmacare and Eli Lilly Respond to Illicit Medicines Amid US Deaths

Urgent Action Required Against Illicit Medicines

Aspen Pharmacare and Eli Lilly are rallying support from the pharmaceutical task group (PTG) to combat the rising issue of illicit medicines. These unregulated drugs, particularly targeted at obesity, have been associated with tragic outcomes, including deaths reported in the US. Retatrutide, a controversial treatment, has drawn attention due to its dangerous implications highlighted by experts from Harvard Medical School.

Collaborative Efforts to Ensure Patient Safety

Leading figures like Pieter Cohen and Stavros Nicolaou stress the importance of collaboration between pharmaceutical companies and health authorities. They emphasize the need for regulatory frameworks to protect patients, especially with the recent scrutiny surrounding drugs marketed without oversight from the US Food & Drug Administration (FDA) and poison centers.